Verona Pharma plc (NASDAQ:VRNA – Get Free Report) saw a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 10,700,000 shares, a growth of 21.0% from the July 31st total of 8,840,000 shares. Based on an average daily volume of 1,480,000 shares, the short-interest ratio is currently 7.2 days.
Verona Pharma Stock Performance
Shares of NASDAQ:VRNA traded up $0.88 during trading on Friday, reaching $26.89. 638,750 shares of the company’s stock traded hands, compared to its average volume of 891,415. The company has a debt-to-equity ratio of 0.72, a current ratio of 8.61 and a quick ratio of 8.61. Verona Pharma has a 12 month low of $11.39 and a 12 month high of $28.83. The company has a 50 day moving average of $21.59 and a 200-day moving average of $17.48. The stock has a market capitalization of $2.15 billion, a P/E ratio of -34.34 and a beta of 0.44.
Verona Pharma (NASDAQ:VRNA – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.53). During the same quarter last year, the company earned ($0.11) EPS. On average, equities analysts expect that Verona Pharma will post -2.07 EPS for the current year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on VRNA shares. Truist Financial boosted their target price on shares of Verona Pharma from $32.00 to $38.00 and gave the stock a “buy” rating in a research report on Friday, June 28th. Canaccord Genuity Group boosted their target price on shares of Verona Pharma from $35.00 to $37.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd. Finally, HC Wainwright boosted their target price on shares of Verona Pharma from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $36.00.
View Our Latest Stock Report on VRNA
Verona Pharma Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
See Also
- Five stocks we like better than Verona Pharma
- Low PE Growth Stocks: Unlocking Investment Opportunities
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- Stock Average Calculator
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- How to Use the MarketBeat Excel Dividend Calculator
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.